Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 8/20 | 0.38 |
| ▸ | CA2 | P00918 | 8/20 | 0.38 |
| ▸ | CA9 | Q16790 | 6/20 | 0.38 |
| ▸ | CA12 | O43570 | 6/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL527977 | 1.00 | MAPT (0.39) | MAPTPKMCA1CA2CA9 | |
| SCHEMBL18947794 | 1.00 | MAPT (0.39) | MAPTPKMCA1CA2CA9 | |
| SCHEMBL15150049 | 1.00 | MAPT (0.39) | MAPTPKMCA1CA2CA9 | |
| SCHEMBL15799019 | 0.86 | NAMPT (0.41) | MAPTPKMCA1CA2CA9 | |
| SCHEMBL17259176 | 0.86 | NAMPT (0.41) | MAPTPKMCA1CA2CA9 | |
| SCHEMBL15805103 | 0.86 | NAMPT (0.41) | MAPTPKMCA1CA2CA9 | |
| SCHEMBL15799018 | 0.86 | NAMPT (0.41) | MAPTPKMCA1CA2CA9 | |
| SCHEMBL25004995 | 0.85 | KMT2A (0.50) | MAPTPKMKMT2A | |
| SCHEMBL18518791 | 0.85 | KMT2A (0.50) | MAPTPKMKMT2A | |
| SCHEMBL15799143 | 0.85 | KMT2A (0.50) | MAPTPKMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3495349-B1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2023-06-28 | — | — | EP | disclosed |
| EP-4074695-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | Oryzon Genomics, S.A. (ES) | 2022-10-19 | — | — | EP | disclosed |
| EP-3736265-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | Oryzon Genomics, S.A. (ES) | 2020-11-11 | — | — | EP | disclosed |
| EP-2768805-B1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2020-03-25 | — | — | EP | disclosed |
| US-10329256-B2 | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors | ORYZON GENOMICS, S.A. (ES) | 2019-06-25 | — | — | US | disclosed |
| EP-3495349-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | Oryzon Genomics, S.A. (ES) | 2019-06-12 | — | — | EP | disclosed |
| EP-2598480-B1 | CYCLOPROPYLAMINE DERIVATIVES USEFUL AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2019-04-24 | — | — | EP | disclosed |
| US-10233178-B2 | Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use | ORYZON GENOMICS, S.A. (ES) | 2019-03-19 | — | — | US | disclosed |
| EP-2776394-B1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2018-12-26 | — | — | EP | disclosed |
| US-20180354902-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS S.A. (ES) | 2018-12-13 | — | — | US | disclosed |
| US-20130289076-A1 | CYCLOPROPYLAMINE INHIBITORS OF OXIDASES | ORYZON GENOMICS S.A. (ES) | 2013-10-31 | — | — | US | disclosed |
| US-20130231342-A1 | ARYLCYCLOPROPYLAMINE BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE | Oryzon Fenomics S.A. (ES) | 2013-09-05 | — | — | US | disclosed |
| US-20130197013-A1 | CYCLOPROPYLAMINE DERIVATIVES USEFUL AS LSD1 INHIBITORS | ORYZON GENOMICS S.A. (ES) | 2013-08-01 | — | — | US | disclosed |
| EP-2598480-A1 | CYCLOPROPYLAMINE DERIVATIVES USEFUL AS LSD1 INHIBITORS | Oryzon Genomics, S.A. (ES) | 2013-06-05 | — | — | EP | disclosed |
| EP-2598482-A1 | ARYLCYCLOPROPYLAMINE BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE | Oryzon Genomics, S.A. (ES) | 2013-06-05 | — | — | EP | disclosed |
| WO-2013057322-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS, S.A. (ES) | 2013-04-25 | — | — | WO | disclosed |
| WO-2013057320-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS, S.A. (ES) | 2013-04-25 | — | — | WO | disclosed |
| WO-2012045883-A1 | CYCLOPROPYLAMINE INHIBITORS OF OXIDASES | ORYZON GENOMICS S.A. (ES) | 2012-04-12 | — | — | WO | disclosed |
| WO-2012013727-A1 | CYCLOPROPYLAMINE DERIVATIVES USEFUL AS LSD1 INHIBITORS | ORYZON GENOMICS S.A. (ES) | 2012-02-02 | — | — | WO | disclosed |
| WO-2012013728-A1 | ARYLCYCLOPROPYLAMINE BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE | ORYZON GENOMICS S.A. (ES) | 2012-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180354902-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | MAPT 334/4885PKM 920/4885CA1 4250/4885 |
| US-10233178-B2 | Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use | KDM6A, KDM1B, KDM1A | MAPT 1531/4885PKM 447/4885CA1 3635/4885 |
| US-20130231342-A1 | ARYLCYCLOPROPYLAMINE BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE | KDM6A, KDM1B, KDM1A | MAPT 1531/4885PKM 447/4885CA1 3635/4885 |
| US-20130289076-A1 | CYCLOPROPYLAMINE INHIBITORS OF OXIDASES | PPOX, MAOB, MAOA | MAPT 3298/4885PKM 1426/4885CA1 2188/4885 |
| US-10329256-B2 | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors | KDM1B, KDM1A, KDM2A | MAPT 334/4885PKM 920/4885CA1 4250/4885 |
| US-20130197013-A1 | CYCLOPROPYLAMINE DERIVATIVES USEFUL AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM3A | MAPT 292/4885PKM 413/4885CA1 3374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.